A randomized phase 2 trial of double-blind, placebo controlled AMG 706 [motesanib] in combination with paclitaxel, or open-label bevacizumab in combination with paclitaxel, as first line therapy in women with HER2 negative locally recurrent or metastatic breast cancer

Trial Profile

A randomized phase 2 trial of double-blind, placebo controlled AMG 706 [motesanib] in combination with paclitaxel, or open-label bevacizumab in combination with paclitaxel, as first line therapy in women with HER2 negative locally recurrent or metastatic breast cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Motesanib (Primary) ; Bevacizumab; Paclitaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Jul 2011 Additional lead trial center identified as reported by Australian New Zealand Clinical Trials Registry.
    • 09 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top